Addison Advisors’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$478K Sell
3,132
-21
-0.7% -$3.22K 0.11% 134
2025
Q4
$435K Buy
3,153
+125
+4% +$16.4K 0.1% 140
2025
Q3
$388K Buy
3,028
+56
+2% +$6.83K 0.09% 147
2025
Q2
$360K Buy
2,972
+236
+9% +$26.6K 0.09% 152
2025
Q1
$305K Sell
2,736
-52
-2% -$5.54K 0.08% 154
2024
Q4
$271K Buy
2,788
+5
+0.2% +$533 0.08% 165
2024
Q3
$320K Buy
2,783
+121
+5% +$13.7K 0.09% 155
2024
Q2
$283K Buy
2,662
+351
+15% +$35.2K 0.09% 154
2024
Q1
$224K Buy
2,311
+22
+1% +$2.26K 0.08% 171
2023
Q4
$231K Buy
2,289
+209
+10% +$20.2K 0.09% 157
2023
Q3
$212K Buy
2,080
+242
+13% +$24.6K 0.1% 145
2023
Q2
$185K Buy
1,838
+181
+11% +$18.1K 0.09% 161
2023
Q1
$152K Sell
1,657
-63
-4% -$5.5K 0.09% 165
2022
Q4
$156K Buy
1,720
+323
+23% +$27.2K 0.09% 148
2022
Q3
$106K Buy
1,397
+112
+9% +$9.28K 0.07% 184
2022
Q2
$109K Sell
1,285
-130
-9% -$11.4K 0.07% 180
2022
Q1
$124K Buy
1,415
+884
+166% +$76.5K 0.07% 191
2021
Q4
$46K Buy
531
+92
+21% +$7.64K 0.03% 254
2021
Q3
$36K Buy
439
+14
+3% +$1.26K 0.03% 209
2021
Q2
$39K Buy
+425
New +$37.8K 0.03% 202
2020
Q4
$40K Buy
+425
New +$37.1K 0.04% 196

Other funds holding NVS

Addison Advisors's NVS Position: Q1 2026 in Review

Addison Advisors reduced its Novartis (NVS) stake by 0.67% in Q1 2026, selling an estimated $3.22K and leaving 3,132 shares worth $478K. The position accounts for 0.11% of the portfolio, ranked #134.

Addison Advisors first reported a position in NVS in Q4 2020 and has held it in 21 quarters since. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Addison Advisors held 3,132 shares of Novartis worth $478K as of Q1 2026.
  • Addison Advisors sold 21 Novartis shares in Q1 2026, an estimated $3.22K.
  • Novartis made up 0.11% of Addison Advisors's portfolio in Q1 2026, its #134 holding.
  • Addison Advisors first reported a position in Novartis in Q4 2020 and has held it in 21 quarters since.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Addison Advisors's 13F filing for Q1 2026, filed 8 May 2026.